Canaccord Genuity Group Trims Medexus Pharmaceuticals (OTCMKTS:MEDXF) Target Price to C$2.75

Medexus Pharmaceuticals (OTCMKTS:MEDXFGet Rating) had its target price trimmed by Canaccord Genuity Group from C$3.50 to C$2.75 in a research report released on Thursday morning, The Fly reports.

Separately, Raymond James downgraded shares of Medexus Pharmaceuticals from an outperform rating to a market perform rating and decreased their price target for the stock from $4.50 to $2.00 in a research note on Tuesday.

Medexus Pharmaceuticals Stock Down 3.4 %

Shares of OTCMKTS:MEDXF opened at $0.82 on Thursday. The company has a 50-day moving average price of $1.78 and a 200-day moving average price of $1.96. Medexus Pharmaceuticals has a 12 month low of $0.79 and a 12 month high of $3.50.

About Medexus Pharmaceuticals

(Get Rating)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.

Featured Stories

The Fly logo

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.